The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Kidney J
Autors principals: Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin, Wanner, Christoph
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Sglt-2 Inhibition
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275453/
https://ncbi.nlm.nih.gov/pubmed/30524708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy090
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars